Subgroup | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | DOR (95% CI) | LR + (95% CI) | LR− (95% CI) | SROC curve AUC ± SE | SROC curve Q* ± SE | |
---|---|---|---|---|---|---|---|---|
Prosp | US | 92 (87–96) | 86 (81–90) | 77 (27–220) | 8.63 (3.21–23.16) | 0.10 (0.06–0.18) | 0.96 ± 0.01 | 0.90 ± 0.02 |
MRI | 93 (88–97) | 91 (87–94) | 96 (24–385) | 8.05 (3.79–17.11) | 0.12 (0.05–0.25) | 0.96 ± 0.02 | 0.91 ± 0.03 | |
Retro | US | 88 (83–92) | 80 (75–85) | 24 (10–57) | 3.55 (2.09–6.03) | 0.21 (0.13–0.34) | 0.90 ± 0.03 | 0.83 ± 0.03 |
MRI | 85 (79–90) | 82 (77–87) | 21 (8–54) | 4.09 (2.52–6.64) | 0.22 (0.13–0.37) | 0.89 ± 0.04 | 0.83 ± 0.04 | |
Earlier studies | US | 90 (83–94) | 88 (83–92) | 51 (16–161) | 6.24 (2.40–16.24) | 0.17 (0.10–0.28) | 0.94 ± 0.02 | 0.88 ± 0.03 |
MRI | 90 (84–95) | 89 (85–93) | 62 (13–305) | 6.77 (2.68–17.11) | 0.14 (0.06–0.33) | 0.97 ± 0.01 | 0.92 ± 0.02 | |
Recent studies | US | 90 (85–94) | 79 (74–84) | 32 (13–78) | 4.38 (2.68–7.15) | 0.16 (0.09–0.27) | 0.91 ± 0.04 | 0.84 ± 0.04 |
MRI | 88 (82–92) | 85 (80–88) | 30 (13–67) | 5.00 (3.79–6.6) | 0.19 (0.11–0.32) | 0.90 ± 0.02 | 0.83 ± 0.02 |